Literature DB >> 3095150

Design of purine nucleoside phosphorylase inhibitors.

J D Stoeckler, S E Ealick, C E Bugg, R E Parks.   

Abstract

Purine nucleoside phosphorylase inhibitors hold promise as specific immunosuppressive, anti-T cell leukemic, and antiuricopoietic agents. The best inhibitors available that are biologically active have Ki values from 10(-6) to 10(-7) M and fall into two categories: noncleavable nucleosides preferably iodinated at the C-5' position and C-8-substituted guanine or acycloguanosines. More potent inhibition is shown by phosphorylated acyclonucleosides that function as multisubstrate analogs, but these compounds are excluded from cells. The X-ray analysis of the human erythrocytic enzyme is beginning to reveal the nature of the active site and to explain the structure-activity relationships that have been established with analog substrates and inhibitors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095150

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  2 in total

1.  Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.

Authors:  S E Ealick; Y S Babu; C E Bugg; M D Erion; W C Guida; J A Montgomery; J A Secrist
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.

Authors:  Adrian S Ray; Loren Olson; Arnold Fridland
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.